![Secalciferol [(24R)-24,25-Dihydroxyvitamin D3]](/upload/0201/CgAH6F3JCy-AO1orAAATQrWQfqg416.png)
| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 2mg | |||
| 5mg | |||
| 10mg | |||
| 25mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Target: Secalciferol activates the vitamin D receptor (VDR) with an EC50 value of 150 nM. It is involved in calcium homeostasis, cell differentiation, proliferation, and immune system functions. The compound mediates calcium and phosphorus homeostasis and is involved in bone ossification.
|
|---|---|
| ln Vitro |
In Vitro Activity: Secalciferol activates vitamin D receptor (VDR) with an EC50 value of 150 nM. It modulates calcium homeostasis and cell differentiation. The compound demonstrates involvement in immune system functions. Detailed in vitro activity data are available from the primary literature.
|
| ln Vivo |
In Vivo Activity: Secalciferol has been studied for potential applications in rickets, osteomalacia, hypercalcemia, and autoimmune diseases. It mediates calcium and phosphorus homeostasis in vivo. The compound is involved in bone ossification and calcium metabolism. It can be used as a marker for Vitamin D3 catabolism and a predictor of serum 25-hydroxycholecalciferol response to Vitamin D3 supplementation.
|
| Enzyme Assay |
In Vitro Enzyme/Receptor Binding Protocol: Vitamin D receptor binding assays typically use recombinant VDR protein or cell extracts. Radioligand binding with [3H]1,25(OH)2D3 is performed with varying concentrations of Secalciferol to determine relative binding affinity and EC50. VDR activation can be assessed using reporter gene assays.
|
| Cell Assay |
In Vitro Cell-Based Assay Protocol: Cells expressing VDR are treated with Secalciferol at various concentrations. VDR activation and downstream gene expression are measured using reporter gene assays or qPCR. Cell proliferation and differentiation assays may also be performed. The compound's effects on calcium homeostasis and immune function can be assessed in appropriate cell models.
|
| Animal Protocol |
In Vivo Animal Assay Protocol: Animal models of rickets, osteomalacia, or autoimmune diseases are used to study Secalciferol. The compound is administered via appropriate routes, and calcium, phosphate, and vitamin D metabolite levels are measured. Bone ossification and histopathology may be assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetics: Secalciferol has molecular formula C27H44O3 and molecular weight 416.64. It is a naturally occurring vitamin D metabolite and the major active metabolite of vitamin D. The compound has melting point 63-65°C, boiling point 571.1°C, and logP 5.85. Detailed pharmacokinetic parameters are similar to other vitamin D metabolites.
|
| Toxicity/Toxicokinetics |
Toxicity: No significant toxicity is associated with Secalciferol at physiological concentrations. As an endogenous metabolite, it is generally well-tolerated. High doses may cause hypercalcemia similar to other vitamin D compounds. The compound is for research use only and is not approved for therapeutic applications.
|
| References | |
| Additional Infomation |
(24R)-24,25-Dihydroxycalcitonol is an open-ring cholesterane, hydroxyopen-ring steroid, and hydroxycalcitonol. It is a human metabolite. Open-ring calcium alcohol has been reported to be detected in Homo sapiens, Streptomyces filamentosa, and Streptomyces sclerotiorum, and relevant data are available. It is a physiologically active metabolite of vitamin D. This compound participates in regulating calcium metabolism, alkaline phosphatase activity, and enhances the calcium-promoting effect of calcitriol.
Additional Information: Secalciferol has CAS number 55721-11-4. It is also known as (24R)-24,25-Dihydroxyvitamin D3. The compound is a human metabolite and has been reported to be detected in Homo sapiens. It is an open-ring cholesterane, hydroxyopen-ring steroid, and hydroxycalcitonol. Secalciferol can be used for the treatment of disorders in calcium and phosphorus homeostasis. For research use only. |
| Molecular Formula |
C27H44O3
|
|---|---|
| Molecular Weight |
416.63646
|
| Exact Mass |
416.329
|
| CAS # |
55721-11-4
|
| Related CAS # |
Secalciferol-d6;1440957-55-0
|
| PubChem CID |
5283748
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
571.1±35.0 °C at 760 mmHg
|
| Melting Point |
63-65ºC
|
| Flash Point |
241.5±20.5 °C
|
| Vapour Pressure |
0.0±3.6 mmHg at 25°C
|
| Index of Refraction |
1.547
|
| LogP |
5.85
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
30
|
| Complexity |
688
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C[C@H](CC[C@H](C(C)(C)O)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C
|
| InChi Key |
FCKJYANJHNLEEP-XRWYNYHCSA-N
|
| InChi Code |
InChI=1S/C27H44O3/c1-18-8-12-22(28)17-21(18)11-10-20-7-6-16-27(5)23(13-14-24(20)27)19(2)9-15-25(29)26(3,4)30/h10-11,19,22-25,28-30H,1,6-9,12-17H2,2-5H3/b20-10+,21-11-/t19-,22+,23-,24+,25-,27-/m1/s1
|
| Chemical Name |
(3R,6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol
|
| Synonyms |
(24R)-24,25-Dihydroxyvitamin D3
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. (3). This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~240.02 mM)
Ethanol : ~50 mg/mL (~120.01 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4002 mL | 12.0008 mL | 24.0015 mL | |
| 5 mM | 0.4800 mL | 2.4002 mL | 4.8003 mL | |
| 10 mM | 0.2400 mL | 1.2001 mL | 2.4002 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA